Journal of Modern OncologyJournal of Modern Oncology1815-14341815-1442LLC Obyedinennaya Redaktsiya27153Research ArticleInterferon α (IFN-α) vs. the combination IFN-α and octreotide LAR in the treatment of patients with well differentiated neuroendocrine tumors (NET) of various localizationsYemelyanovaG Sdocgalina@mail.ruKuzminovA E-OrelN F-MarkovichA A-KuznetsovaA A-GorbunovaV A-I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian FederationN.N.Blokhin Russian Cancer Reseach Center of the Ministry of Health of the Russian FederationRussian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation15062017192616509042020Copyright © 2017, Consilium Medicum2017It is still unknown whether the combination of IFN-α with octreotide has benefit compared with IFN-α alone. We compared efficacy and toxicyty of IFN-α and IFN-α plus octreotide in first line of therapy of patients with NETs. There was trend to longer TTP in lung NETs pts comparing with GEP NETs pts treated with IFN-α. IFN-α may be a therapy of choice in pts with well differentiated lung NETs as first line treatment. IFN-α have a similar toxicity profile comparing with IFN-α combined with octreotide.neuroendocrine tumorsinterferon αнейроэндокринные опухолиинтерферон α[Hofland L.J, de Herder W.W, Lamberts S.W.J. Mechanism of action of somatostatin and interferon in gastroenteropancreatic tumours. In The expanding role of octreotide I: advances in oncology. SWJ Lamberts & Dogliotti (eds.) 2002; p. 89-102.][Funa К, Alm G.V, Rönnblom L, Oberg K. Evaluation of the natural killer cell - interferon system in patients with mid - gut carcinoid tumours treated with leucocyte interferon. Clin Exp Immunol 1983; 53 (3): 716-24.][Aparicio-Pagés M.N, Verspaget H.W, Peña A.S et al. Natural killer cell activity in patients with neuroendocrine tumours of the gastrointestinal tract; relation with circulating gastrointestinal hormones. Neuropeptides 1991; 20 (1): 1-7.][Rosewicz S, Detjen K, Scholz A, von Marschall Z. Interferon - alpha: regulatory effects on cell cycle and angiogenesis. Neuroendocrinology; 2004: 80 (1): 85-93.][Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 2001; 12 (S1): 111-4.][Eriksson В, Oberg K. Interferon therapy of malignant endocrine pancreatic tumors. Endocrine Tumors of the Pancreas: Recent Advanced in Research and Management, 1995; p. 451-60.][Oberg K. Interferon in the management of neuroendocrine GEP_tumors. Digest 2000; 62 (Suppl. 1): 92-7.][Arnold R, Rinke A, Klose K.J et al. Octreotide versus octreotide plus interferon - alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 2005; 3 (8): 761-71.][Kolby L, Persson G, Franzen S, Ahren B. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 2003; 90: 687-93.][Yao J, Guthrie K, Moran C et al. SWOG S0518: Phase III prospective randomized comparison of depot octreotide plus interferon alpha-2b versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients (NCT00569127). J Clin Oncol 2015; 33 (Suppl.; abstr 4004).][Travis W.D, Brambilla E, Müller-Hermelink H.K et al. (eds.). Pathology & Genetics tumours of the lung, pleura, thymus and heart. Lyon: IARC Press, 2004.][Modlin I.M, Lye K.D, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934-59.][Yao J.C, Hassan M, Phan A et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-72.][Surveillance, Epidemiology, and End Results Program: Lung Cancer histologically confirmed SEER 18 registries research data plus Hurricane Katrina impacted Louisiana cases 1973-2010, November 2012.][Sakurai H, Asamura H. Large - cell neuroendocrine carcinoma of the lung: surgical management. Thorac Surg Clin 2014; 24: 305-11.][Oberg K, Hellman P, Kwekkeboom D et al. Neuroendocrine bronchial and thymic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow - up. Ann Oncol 2010; 21 (Suppl. 5): v220-2.][Fink G, Krelbaum T, Yellin A et al. Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest 2001; 119: 1647-51.][Filosso P.L, Oliaro A, Ruffini E et al. Outcome and prognostic factors in bronchial carcinoids: a single - center experience. J Thorac Oncol 2013; 8: 1282-8.]